English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Abnormal RAS/RAF signaling plays a critical role in glioma. Although it is known that the V600E mutation of v-raf murine viral oncogene homolog B1 ( BRAF   V600E ) and  BRAF  amplification ( BRAF   AMP ) both result in constitutive activation of the RAS/RAF pathway, whether  BRAF   V600E  and  BRAF   AMP  have different effects on the survival of glioma patients needs to be clarified. Using cBioPortal, we retrieved studies of both mutations and copy number variations of the  BRAF  gene in CNS/brain tumors and investigated data from 69 nonredundant glioma patients. The  BRAF  mutation group had significantly more male patients (64.00% vs. 36.84%;  P  = 0.046) and a higher occurrence of glioblastoma multiforme (66.00% vs. 31.58%;  P  = 0.013) compared to those in the other group. The  BRAF   AMP  group had significantly more patients with the mutant isocitrate dehydrogenase 1 and 2 ( IDH1/2 ) (73.68% vs. 18.00%;  P  = 0.000), tumor protein p53 ( TP53 ) (73.68% vs. 30.00%;  P  = 0.002), and alpha thalassemia/mental retardation syndrome X linked ( ATRX ) (63.16% vs. 18.00%;  P  = 0.001) than the mutation group. The  BRAF   AMP  and  IDH1/2   WT  cohort had lower overall survival compared with the  BRAF   AMP  and  IDH1/2   MT  groups ( P  = 0.001) and the  BRAF  mutation cohort ( P  = 0.019), including the  BRAF   V600E  ( P  = 0.033) and  BRAF   non-V600E  ( P  = 0.029) groups, using Kaplan–Meier survival curves and the log rank (Mantel–Cox) test. The  BRAF   AMP  and  IDH1/2   WT  genotype was found to be an independent predictive factor for glioma with  BRAF  mutation and  BRAF   AMP  using  Cox  proportional hazard regression analysis (HR = 0.138,  P  = 0.018). Our findings indicate that  BRAF   AMP  frequently occurs with  IDH1/2 ,  TP53 , and  ATRX  mutations. Adult patients with glioma with  BRAF   AMP  and  IDH1/2   WT  had worse prognoses compared with those with  BRAF  mutation and  BRAF   AMP  and  IDH1/2   MT . This suggests that the assessment of the status of  BRAF   AMP  and  IDH1/2  in adult glioma/glioblastoma patients has prognostic value as these patients have relatively short survival times and may benefit from personalized targeted therapy using  BRAF  and/or MEK inhibitors.

frontiers in oncology

BRAFAMP Frequently Co-occurs With IDH1/2, TP53, and ATRX Mutations in Adult Patients With Gliomas and Is Associated With Poorer Survival Than That of Patients Harboring BRAFV600E